RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sinopharm Group Co Stock

Sinopharm Group Co EBIT 2024

Sinopharm Group Co EBIT

23.44 B CNY

Ticker

1099.HK

ISIN

CNE100000FN7

WKN

A0N99U

In 2024, Sinopharm Group Co's EBIT was 23.44 B CNY, a 5.21% increase from the 22.28 B CNY EBIT recorded in the previous year.

The Sinopharm Group Co EBIT history

YEAREBIT (undefined CNY)
2028e31.48
2027e29.39
2026e27.77
2025e25.54
2024e23.44
202322.28
202222.54
202120.84
202019.03
201918.09
201815.75
201713.14
201610.21
20159.23
20147.86
20136.1
20124.86
20113.64
20102.41
20091.55
20081.17
20070.79
20060.48

Sinopharm Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sinopharm Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sinopharm Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sinopharm Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sinopharm Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sinopharm Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sinopharm Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sinopharm Group Co’s growth potential.

Sinopharm Group Co Revenue, EBIT and net profit per share

DateSinopharm Group Co RevenueSinopharm Group Co EBITSinopharm Group Co Net Income
2028e753.31 B undefined31.48 B undefined3.91 B undefined
2027e729.68 B undefined29.39 B undefined3.65 B undefined
2026e776.83 B undefined27.77 B undefined5.24 B undefined
2025e716.63 B undefined25.54 B undefined4.77 B undefined
2024e659.13 B undefined23.44 B undefined4.34 B undefined
2023596.57 B undefined22.28 B undefined9.05 B undefined
2022552.15 B undefined22.54 B undefined8.53 B undefined
2021521.05 B undefined20.84 B undefined7.76 B undefined
2020456.41 B undefined19.03 B undefined7.19 B undefined
2019425.27 B undefined18.09 B undefined6.25 B undefined
2018344.53 B undefined15.75 B undefined5.84 B undefined
2017308.35 B undefined13.14 B undefined5.58 B undefined
2016258.39 B undefined10.21 B undefined4.65 B undefined
2015228.67 B undefined9.23 B undefined3.77 B undefined
2014200.13 B undefined7.86 B undefined2.87 B undefined
2013166.87 B undefined6.1 B undefined2.25 B undefined
2012135.79 B undefined4.86 B undefined1.97 B undefined
2011102.23 B undefined3.64 B undefined1.56 B undefined
201069.23 B undefined2.41 B undefined1.21 B undefined
200947.05 B undefined1.55 B undefined846 M undefined
200838.19 B undefined1.17 B undefined586 M undefined
200731.11 B undefined789 M undefined381 M undefined
200623.74 B undefined480 M undefined101 M undefined

Sinopharm Group Co stock margins

The Sinopharm Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sinopharm Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sinopharm Group Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sinopharm Group Co's sales revenue. A higher gross margin percentage indicates that the Sinopharm Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sinopharm Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sinopharm Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sinopharm Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sinopharm Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sinopharm Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sinopharm Group Co Margin History

Sinopharm Group Co Gross marginSinopharm Group Co Profit marginSinopharm Group Co EBIT marginSinopharm Group Co Profit margin
2028e8.13 %4.18 %0.52 %
2027e8.13 %4.03 %0.5 %
2026e8.13 %3.57 %0.67 %
2025e8.13 %3.56 %0.66 %
2024e8.13 %3.56 %0.66 %
20238.13 %3.73 %1.52 %
20228.59 %4.08 %1.54 %
20218.45 %4 %1.49 %
20208.83 %4.17 %1.57 %
20198.83 %4.25 %1.47 %
20189.06 %4.57 %1.69 %
20178.45 %4.26 %1.81 %
20168 %3.95 %1.8 %
20158.19 %4.04 %1.65 %
20148.16 %3.93 %1.44 %
20138.02 %3.66 %1.35 %
20128.06 %3.58 %1.45 %
20118.17 %3.56 %1.53 %
20108.43 %3.48 %1.75 %
20098.05 %3.29 %1.8 %
20087.95 %3.07 %1.53 %
20078.2 %2.54 %1.22 %
20068.38 %2.02 %0.43 %

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Sinopharm Group Co's EBIT

Sinopharm Group Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sinopharm Group Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sinopharm Group Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sinopharm Group Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sinopharm Group Co stock

How much did Sinopharm Group Co achieve in EBIT for the current year?

In the current year, Sinopharm Group Co has achieved an EBIT of 23.44 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Sinopharm Group Co.

How has the EBIT of Sinopharm Group Co developed in recent years?

The EBIT of Sinopharm Group Co has increased by 5.212% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Sinopharm Group Co?

The EBIT of Sinopharm Group Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.9 CNY . This corresponds to a dividend yield of about 5.54 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 0.98 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 5.54 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 19 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 0.98 CNY are expected. This corresponds to a dividend yield of 6.01 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/13/2024 amounting to 0.956 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/13/2024.

What was the dividend of Sinopharm Group Co in the year 2023?

In the year 2023, Sinopharm Group Co distributed 0.872 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinopharm Group Co

Our stock analysis for Sinopharm Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinopharm Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.